HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

RGEN

Repligen Corporation (NASDAQ)

Healthcare — Medical Instruments & Supplies

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Buy 1.5 / 5 19 analysts
$138.99
+$2.55 (+1.87%)
Target: $176.11 (26.7%)
Sign in to add RGEN to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$7.84B
P/E Ratio (TTM)154.43
Forward P/E54.56
EPS (TTM)$0.90
Dividend Yield-
Profit Margin6.73%
Revenue Growth14.80%
ROE2.51%
Debt/Equity32.66
Recommendation Buy 1.5
Analyst Target$176.11
Analysts19
Indexes NASDAQ

Technical Indicators

RSI (14)58.4
Beta1.08
SMA 20-
SMA 40-
52-Week High$175.77
52-Week Low$100.99
50-Day Avg$123.05
200-Day Avg$138.90
Avg Volume$1.15M
Volume$1.16M

Performance Analysis

BULLISH

RGEN shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 51% of its 52-week range.
+ RSI at 58.4 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 154.4 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 14.8% year-over-year.
+ Wall Street consensus is "Buy" from 19 analysts.
+ Average analyst target of $176.11 implies 26.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:29 UTC

Back to Screener Export Report